Drug Trial Radar · NCT07653477
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
956
Planned (sponsor's estimate)
Start
Sep 7, 2026
Primary completion
Feb 29, 2028
Study completion Feb 29, 2028
Sponsor
- Lead sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, open-label, parallel-group, semaglutide injection-controlled clinical trial. It aims to evaluate the non-inferiority of UBT251 Injection in glycemic control compared with Semaglutide Injection after 40 weeks of continuous administration in study participants with Type 2 Diabetes Mellitus (T2DM) and inadequate glycemic control on oral antidiabetic medications.A total of 956 participants are planned to be enrolled, including the UBT251 Injection 2 mg group, 4 mg group, 6 mg group, and Semaglutide group,with an approximate study duration of 58 weeks per participant.
Conditions
- Type 2 Diabetes
Interventions
UBT251 Injection 2.0 mg groupDrug
UBT251 Injection subcutaneously once weekly
UBT251 Injection 4.0 mg groupDrug
UBT251 Injection subcutaneously once weekly
UBT251 Injection 6.0 mg groupDrug
UBT251 Injection subcutaneously once weekly
Semaglutide InjectionDrug
Semaglutide Injection subcutaneously once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1cTime frame: Week 40
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital,Fudan University
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.